Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel With and Without Nivolumab, and Nivolumab + Cabozantinib in Angiosarcoma
NCT04339738Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2020
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab, cabozantinib in angiosarcoma, sponsored by National Cancer Institute. Started Nov 2020; status: active, not recruiting.
02
Drugs
nivolumabcabozantinib
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT04339738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339738.